Related Experiment Video
Updated: Dec 27, 2025
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Biomarkers in retinoblastoma
Jie Sun1, Hui-Yu Xi1,2, Qing Shao1
1Department of Ophthalmology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Abstract:
Retinoblastoma (RB) is the most common intraocular malignancy of childhood caused by inactivation of the Rb genes. The prognosis of RB is better with an earlier diagnosis. Many diagnostic approaches and appropriate clinical treatments have been developed to improve clinical outcomes. However, limitations exist when utilizing current methods. Recently, many studies have identified identify new RB biomarkers which can be used in diagnosis, as prognostic indicators and may contribute to understanding the pathogenesis of RB and help determine specific treatment strategies. This review focuses on recent advances in the discovery of RB biomarkers and discusses their clinical utility and challenges from areas such as epigenetics, proteomics and radiogenomics.
Insights
New biomarkers for retinoblastoma (RB), a common childhood eye cancer, offer improved diagnosis and treatment strategies. This review explores recent advances in RB biomarker discovery and their clinical applications.
Area of Science:
- Ophthalmology
- Oncology
- Genetics
Background:
- Retinoblastoma (RB) is the most frequent intraocular cancer in children.
- RB is caused by the inactivation of the *Rb* genes.
- Early diagnosis significantly improves patient prognosis.
Purpose of the Study:
- To review recent advancements in the discovery of novel retinoblastoma biomarkers.
- To discuss the clinical utility and challenges of these biomarkers.
- To explore biomarker contributions to understanding RB pathogenesis and treatment strategies.
Main Methods:
- Literature review of recent studies on RB biomarkers.
- Focus on epigenetics, proteomics, and radiogenomics.
- Analysis of biomarker diagnostic and prognostic potential.
Main Results:
- Numerous new RB biomarkers have been identified.
- These biomarkers show potential in diagnosis and prognosis.
- Emerging research areas like epigenetics, proteomics, and radiogenomics are yielding promising findings.
Conclusions:
- New biomarkers are crucial for improving retinoblastoma diagnosis and treatment.
- Further research is needed to overcome challenges in clinical utility.
- Biomarker discovery aids in understanding RB pathogenesis and personalizing treatment.
